語系:
繁體中文
English
說明(常見問題)
回圖書館首頁
手機版館藏查詢
登入
回首頁
到查詢結果
[ subject:"Molecular biology." ]
切換:
標籤
|
MARC模式
|
ISBD
Targeting mTOR in Pancreatic Cancer.
~
Soares, Heloisa Prado.
FindBook
Google Book
Amazon
博客來
Targeting mTOR in Pancreatic Cancer.
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
Targeting mTOR in Pancreatic Cancer./
作者:
Soares, Heloisa Prado.
面頁冊數:
118 p.
附註:
Source: Dissertation Abstracts International, Volume: 76-09(E), Section: B.
Contained By:
Dissertation Abstracts International76-09B(E).
標題:
Molecular biology. -
電子資源:
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3702708
ISBN:
9781321741476
Targeting mTOR in Pancreatic Cancer.
Soares, Heloisa Prado.
Targeting mTOR in Pancreatic Cancer.
- 118 p.
Source: Dissertation Abstracts International, Volume: 76-09(E), Section: B.
Thesis (Ph.D.)--University of California, Los Angeles, 2015.
Pancreatic ductal adenocarcinoma (PDAC), which comprises 90% of all human pancreatic cancers, is a devastating disease with overall 5-year survival rate of only 5%. A major challenge is to identify novel targets and develop strategies for its treatment. New approaches will most likely arise from a detailed understanding of the molecular signaling pathways that stimulate the unrestrained proliferation of these cells. The PI3K/AKT/mTOR pathway plays a pivotal role in pancreatic cancer. Several drugs, including mTOR kinase inhibitors, are in development to target this pathway. In addition to growth-promoting signaling, the mTORC1/S6K axis also mediates negative feedback loops that restrict signaling via insulin/IGF receptor and other tyrosine kinase receptors and can lead to drug resistance. In this dissertation, I describe studies performed in PDAC cell lines using different inhibitors of the mTOR pathway, including: a) rapamycyn, an allosteric mTOR inhibitor; b) PP242 and KU63794, active-site mTOR inhibitors; c) NVP-BEZ235, GDC-0980 and PKI-587, dual PI3K/mTOR inhibitors, d) metformin and berberine, two anti-diabetics drugs with emerging promising anti-cancer properties. We show that active-site mTOR and dual PI3K/mTOR inhibitors induce an unexpected increase in the activity of the ERK pathway in PDAC cells. Additionally, we demonstrate that ERK over-activation can be abrogated by the use of MEK inhibitors. We also show that metformin and berberine are capable of inhibiting mTOR signaling without ERK over-activation. Our mechanistic studies demonstrate that dual PI3K/mTOR inhibitors suppress a novel PI3K-independent negative feedback loop mediated by mTORC2 thereby leading to enhancement of MEK/ERK pathway activity in pancreatic cancer cells. Finally, we review negative feedback mechanisms that restrain signaling via upstream elements of the PI3K/AKT/mTOR pathway as well as mechanisms leading to the compensatory activation of other pro-oncogenic pathways, including MEK/ERK. Taken together, the data presented in this dissertation have important translational applications and provide a rationale for the study of combinatory target therapy in pancreatic cancer.
ISBN: 9781321741476Subjects--Topical Terms:
517296
Molecular biology.
Targeting mTOR in Pancreatic Cancer.
LDR
:03081nmm a2200277 4500
001
2066779
005
20160204121818.5
008
170521s2015 ||||||||||||||||| ||eng d
020
$a
9781321741476
035
$a
(MiAaPQ)AAI3702708
035
$a
AAI3702708
040
$a
MiAaPQ
$c
MiAaPQ
100
1
$a
Soares, Heloisa Prado.
$3
3181626
245
1 0
$a
Targeting mTOR in Pancreatic Cancer.
300
$a
118 p.
500
$a
Source: Dissertation Abstracts International, Volume: 76-09(E), Section: B.
500
$a
Includes supplementary digital materials.
500
$a
Adviser: Enrique Rozengurt.
502
$a
Thesis (Ph.D.)--University of California, Los Angeles, 2015.
520
$a
Pancreatic ductal adenocarcinoma (PDAC), which comprises 90% of all human pancreatic cancers, is a devastating disease with overall 5-year survival rate of only 5%. A major challenge is to identify novel targets and develop strategies for its treatment. New approaches will most likely arise from a detailed understanding of the molecular signaling pathways that stimulate the unrestrained proliferation of these cells. The PI3K/AKT/mTOR pathway plays a pivotal role in pancreatic cancer. Several drugs, including mTOR kinase inhibitors, are in development to target this pathway. In addition to growth-promoting signaling, the mTORC1/S6K axis also mediates negative feedback loops that restrict signaling via insulin/IGF receptor and other tyrosine kinase receptors and can lead to drug resistance. In this dissertation, I describe studies performed in PDAC cell lines using different inhibitors of the mTOR pathway, including: a) rapamycyn, an allosteric mTOR inhibitor; b) PP242 and KU63794, active-site mTOR inhibitors; c) NVP-BEZ235, GDC-0980 and PKI-587, dual PI3K/mTOR inhibitors, d) metformin and berberine, two anti-diabetics drugs with emerging promising anti-cancer properties. We show that active-site mTOR and dual PI3K/mTOR inhibitors induce an unexpected increase in the activity of the ERK pathway in PDAC cells. Additionally, we demonstrate that ERK over-activation can be abrogated by the use of MEK inhibitors. We also show that metformin and berberine are capable of inhibiting mTOR signaling without ERK over-activation. Our mechanistic studies demonstrate that dual PI3K/mTOR inhibitors suppress a novel PI3K-independent negative feedback loop mediated by mTORC2 thereby leading to enhancement of MEK/ERK pathway activity in pancreatic cancer cells. Finally, we review negative feedback mechanisms that restrain signaling via upstream elements of the PI3K/AKT/mTOR pathway as well as mechanisms leading to the compensatory activation of other pro-oncogenic pathways, including MEK/ERK. Taken together, the data presented in this dissertation have important translational applications and provide a rationale for the study of combinatory target therapy in pancreatic cancer.
590
$a
School code: 0031.
650
4
$a
Molecular biology.
$3
517296
690
$a
0307
710
2
$a
University of California, Los Angeles.
$b
Molecular Biology 0573.
$3
2102169
773
0
$t
Dissertation Abstracts International
$g
76-09B(E).
790
$a
0031
791
$a
Ph.D.
792
$a
2015
793
$a
English
856
4 0
$u
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3702708
筆 0 讀者評論
館藏地:
全部
電子資源
出版年:
卷號:
館藏
1 筆 • 頁數 1 •
1
條碼號
典藏地名稱
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
W9299647
電子資源
11.線上閱覽_V
電子書
EB
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
評論
新增評論
分享你的心得
Export
取書館
處理中
...
變更密碼
登入